The trajectory of companies tied to flagship drugs like Viagra presents a nuanced investment landscape . While the initial rise of copyright, fueled by Viagra's unprecedented popularity, generated substantial returns, the expiry in key regions has introduced substantial risk . Pharma Investors are now grappling with the impact of generic competitio